StockNews.com Upgrades LivaNova (NASDAQ:LIVN) to Strong-Buy

LivaNova (NASDAQ:LIVN - Get Free Report) was upgraded by investment analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Wednesday.

Other equities research analysts also recently issued research reports about the company. Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, October 31st. Needham & Company LLC reissued a "buy" rating and set a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group began coverage on shares of LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, LivaNova has an average rating of "Buy" and an average target price of $69.17.

LivaNova Stock Performance

Shares of NASDAQ:LIVN remained flat at $47.63 on Wednesday. 554,533 shares of the company's stock were exchanged, compared to its average volume of 468,526. LivaNova has a 1 year low of $43.15 and a 1 year high of $64.47. The company's fifty day moving average price is $49.74 and its two-hundred day moving average price is $50.20. The firm has a market cap of $2.59 billion, a P/E ratio of 113.40 and a beta of 0.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.27% of the company's stock.

Hedge Funds Weigh In On LivaNova

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova during the second quarter worth $88,000. Central Pacific Bank Trust Division bought a new stake in LivaNova during the 3rd quarter worth $178,000. Captrust Financial Advisors acquired a new position in LivaNova in the 3rd quarter worth about $217,000. Sanctuary Advisors LLC acquired a new position in LivaNova in the 3rd quarter worth about $219,000. Finally, Edgestream Partners L.P. bought a new position in LivaNova in the third quarter valued at about $244,000. Institutional investors own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.